A Phase 2 Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222720

Enrollment

400

Registered

2015-01-16

Start date

2015-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Esaxerenone Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Male and female subjects aged 20 years or older at informed consent 2)Subjects with essential hypertension (Sitting SBP >= 140 mmHg and = 90 mmHg and < 110 mmHg, and 24hr blood pressure more than 130 mmHg in SBP and 80 mmHg in DBP)

Exclusion criteria

Exclusion criteria: 1)Secondary hypertension or malignant hypertension 2)Diabetes mellitus with albuminuria 3)Serum potassium level = 5.1 mEq/L 4)Reversed day-night life cycle including overnight workers 5)eGFR < 60 mL/min/1.73 m^2

Design outcomes

Primary

Measure	Time frame
safety efficacy Change from baseline in sitting systolic and diastolic blood pressure Adverse event	—

Secondary

Measure	Time frame
safety efficacy Change from baseline in 24-hr blood pressure (ABPM) Change in serum potassium	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026